![](/img/cover-not-exists.png)
A20Rechallenge with cetuximab (cet) + irinotecan (iri) in 3rd-line in RAS and BRAF wt metastatic colorectal cancer (mCRC) patients (pts) with acquired resistance to 1st-line cet + iri: the phase II CRICKET study by GONO
Santini, D, Cremolini, C, Salvatore, L, Lonardi, S, Dell'Aquila, E, Cattaneo, M, Loupakis, F, Rossini, D, Vincenzi, B, Ziampiri, S, Buoro, V, Tamburini, E, Basile, D, Corsi, D C, Fioroni, I, Masi, G,Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx422.019
Date:
October, 2017
File:
PDF, 50 KB
english, 2017